COMPANY RESEARCHA Japanese CMC contract research company combining solid-form selection with high-throughput nucleation, competitive slurry conversion, and structure determination.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
The website's solid-state technology pages and technical articles describe salt, cocrystal, and polymorph screening and competitive slurry conversion.
The company also explicitly offers contract 3D ED / MicroED structure analysis.
The website explicitly offers client 3D ED / MicroED structure analysis and presents a selexipag case study.
Listed applications include structural analysis of polymorphs, individual mixture components, salts, cocrystals, and ground tablets.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| Solid-state R&D capabilities | Determined by the submitted sample and research question · Not applicable; service capability | Services / platform | Not applicable; not a human clinical program |
| MicroED / 3D ED service capabilities | Determined by the submitted sample and research question · Not applicable; service capability | Services / platform | Not applicable; not a human clinical program |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
This article explores how Microcrystal Electron Diffraction (MicroED) is set to revolutionize drug polymorph research workflows. Drawing upon recent news, official websites, and LinkedIn updates from Crystal Pharmatech and Eldico, it clearly distinguishes between verified facts, industry viewpoints, and information pending verification.
Direct Electron lists a REyes webinar for November 10, 2026, at noon Eastern Time. It will discuss diffraction-guided screening, automated acquisition and structure solution, including integration with SerialEM.
Crystal Pharmatech’s November 4 announcement confirms ED-1 service in Suzhou. Its service page describes integration with solid-form screening for small crystals and pharmaceutical solid forms.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.